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The cellular prion protein PrPC is synthesized 
as a family of four distinct forms. Of these, 
CytPrP is a minor member that segregates 
outside of the secretory route and can generate 
cytotoxic forms. Using signal sequence 
mutants, we found that CytPrP is translated 
from a downstream AUG (coding for M8 in 
HuPrP or M15 in HaPrP). Shortening of the 
signal sequence dictated the spillage of this 
isoforms into the cytosol, from where it 
accessed the nucleus or formed insoluble 
cytosolic aggregates if the proteasome is 
inhibited. The PrP isoform isolated from the 
nuclear fractions of cell and brain 
homogenates was partially SUMO-1 
conjugated. Expression of HaPrP(M15) in cells 
caused an anti-proliferative phenotype due to a 
cell cycle arrest at the G0/G1 phase. The 
identification of this PrP isoform and its 
properties provides novel insight into PrPC 
physiological and pathological functions. 
 
The cellular prion protein (PrPC) underlies 
a group of fatal neurodegenerative diseases 
through its conversion into self-perpetuating and 
neurotoxic forms [1-4]. Despite a large amount of 
evidence supporting a role in survival-death and 
growth-differentiation cell decisions, the 
physiological function of PrPC and its 
involvement in disease remain elusive [5-8]. A 
crucial limiting factor for PrPC functional 
determination is its molecular diversity. Although 
PrPC is mainly thought of as a glycoprotein 
attached to the cell surface by a 
glycosylphosphatidylinositol anchor, PrPC is 
actually synthesized as a family of four members: 
the membrane anchored glycoprotein (SecPrP), two 
transmembrane forms with opposite topologies 
(NtmPrP and CtmPrP) and a soluble form (CytPrP) [3, 
9-12].   
Of these different members, CytPrP 
accounts for a minor intracellular subset of PrPC 
that has attracted much attention because its 
accumulation sensitizes cells to death [13-15]. 
Initially, CytPrP was thought to be formed by 
misfolded chains that retrotranslocated through 
the endoplasmic reticulum-associated protein 
degradation-proteasome pathway [16,17]. 
However, it was later shown that CytPrP is 
constitutively populated by nascent chains that 
spill into the cytosol due to inefficient N-terminal 
signalling [15,18]. Regarding the role of CytPrP, 
most knowledge has been provided by models 
consisting of mutant polypeptide chains that are 
inappropriately expressed and folded in the 
cytosol. These PrP(23-230) chains exhibit a 
widespread intracellular distribution [19-21] and 
an allegedly role that varies from cytotoxic 
[14,20] to innocuous or even protective 
[19,22,23]. These contradictions call into question 
the fidelity with which such models can describe 
CytPrP.  
The finding that information for CytPrP 
synthesis is contained in its N-terminal signal 
sequence [15] prompted us to decipher this code 
and use it as a tool to isolate its synthesis from 
that of the major forms and inspect its function. 
We have found that CytPrP is indeed a novel PrP 
isoform that access the nucleus and interferes with 
cell growth. These results provide new insights on 
PrP diversity and its role in health and disease. 
 
 
EXPERIMENTAL PROCEDURES 
 
Plasmid construction and recombinant 
standard production. The plasmid pcDNA4-
HaPrP, kindly provided by Dr. RS Hegde, was 
first mutated to introduce the 6 nucleotides from 
the 5´-UTR region adjacent to the initial ATG in 
order to preserve the wild type Kozak sequence. 
HuPrP ORF was cloned into pcDNA3.1 at 
BamHI/EcoRI sites preserving the corresponding 
 -2-
wild type Kozak region. Wild-type constructs 
were used as templates to generate different 
mutants (Table 1, Figure 1) by using Quickchange 
protocols (Stratagene). The integrity of each 
construct was verified by sequencing. 
Recombinant PrP chains (rPrP) of 1-254, 15-231, 
15-254 and 23-231 were produced from the 
corresponding pET11a plasmids in E.coli 
BL21(DE3) and used as inclusion bodies 
denatured extracts as previously described [5]. 
 
Transcription, translation and translocation 
assays. All plasmids were enzymatically 
linearized (pcDNA4.1-HaPrP plasmids with ApaI 
and pcDNA3.1-HuPrP constructs with SacII) and 
then transcribed with the T7 CapScribe kit 
(Promega). After integrity verification, the 
transcribed mRNAs were translated at 80 µg/ml 
final concentration using 50% (v/v) nuclease-
treated rabbit reticulocyte lysate system 
(Promega) and RedivueTM L-[35S]methionine 
(Amersham Biosciences), as indicated by the 
manufacturer. For translation-translocation assays, 
the reaction mixture was enriched in 15% (v/v) 
canine pancreatic rough microsomal membranes 
[24, and references therein]. Isolation of the 
fraction of sealed microsomes from the reaction 
mixtures was performed by discontinuous sucrose 
gradient ultracentrifugation as previously 
described [24]. For protease protection analysis, 
the total reaction mixtures and their sealed 
microsomal fractions were incubated for 1 h at 
4oC with 0.1 mg/ml proteinase K (Roche 
Diagnostics) both in the absence and presence of 
0.5 % Triton X-100. The reaction was stopped 
with 5 mM PMSF. The 35S-labeled reaction 
products were immunoprecipitated with αPrP 3F4 
mAb (Signet Lab), resolved on Tris-Tricine 
16.5% PAGE-SDS gels and visualized using a 
PhosphorImager (Fuji Fla 3000). Enzymatic 
deglycosylation was performed by incubating the 
immunoprecipitated samples with PNGase F 
(New England BioLabs) according to the 
manufacturer´s instructions. 
 
Cell culture, transfections and treatments. 
CHO and COS-7 cells were grown and 
maintained in DMEM supplemented with 10% 
fetal bovine serum, 2 mM glutamine, 10 IU/ml 
penicillin, and 10 µg/ml streptomycin in a 
humidified atmosphere of 5% CO2 at 37°C. 
Transfection of cells with the different plasmids 
was performed with TransIT-LT1 (Mirus) 
following the manufacturer´s indications. After 48 
h, cells were processed for analysis or used for 
bulk selection of stable transfectants. For 
proteasome impairment experiments, 24 h after 
transfection cells were treated in the absence or 
presence of 5 µM MG132 for 18 h [15]. 
Alternatively, after 4h the medium was changed 
and the incubation was continued for another 14h 
[15]. After PBS washes, cells were harvested and 
analyzed for protein aggregation (see below). 
 
Cell lysates, brain homogenates and 
fractionations. Denatured cell lysates were 
prepared at about 15 mg/ml protein concentration 
in 62.5 mM Tris-HCl pH 6.8 containing 4% SDS 
(w/v) and 25% glycerol (w/v), boiled for 10 min 
and then cleared by centrifugation at 15000xg for 
20 min. Hamster brains were obtained from the 
Animal Facility of the Instituto de Investigaciones 
Biomédicas “Alberto Sols” UAM-CSIC. Human 
cortex control samples were obtained from the 
Institute of Neuropathology and University of 
Barcelona/Clinic Hospital brain banks following 
the guidelines of the local ethics committees. 
Tissue homogenates at 10% (w/v) were prepared 
in PBS pH 7.5, containing 0.25 M sucrose, 1.5 
mM sodium orthovanadate, 5 mM EDTA and the 
EDTA-free Complete protein inhibitor cocktail 
(Roche Diagnostics), aliquoted and kept at -80 oC. 
Fractionation of cell and tissue homogenates into 
nuclear and post-nuclear fractions was performed 
using the Pure Prep Nuclei isolation kit (Sigma) 
following the manufacturer indications. The final 
step including PIPLC digestion was introduced to 
ensure the removal of contaminant raft-resident 
PrPC. 
Protein aggregation assays. Analysis of PrP 
aggregation upon proteasome inhibition was 
performed with minor modifications to published 
methods [13, 15-17]. Cells were lysed in cold EZ-
lysis buffer and then separated into pellet 
(nuclear) and supernatant (post-nuclear) fractions 
by a 500xg centrifugation for 10 min at 4 oC. The 
pellets were washed twice with EZ-lysis buffer for 
isolation of the nuclear fractions. The post-nuclear 
supernatants were supplemented with 0.5% Triton 
X-100 and 0.5% deoxycholate, dispersed by 
extensive pipetting and then centrifuged for 10 
min at 13,000xg at 4oC. Proteins in the 
supernatant were precipitated with cold 15%TCA. 
All protein pellets were resuspended in 0.1M Tris-
HCl pH 8.0, 1% SDS and equal aliquots of each 
fraction were analyzed by SDS-PAGE and 
immunoblotting. 
 
Immunoprecipitation and western blotting. 
Samples were lysed in 62.5 mM Tris-HCl pH 6.8 
containing 4 % (w/v) SDS and 25 % (w/v) 
glycerol. After a 10 min spin at 10000xg, the 
supernatants were diluted 1:40 with PBS pH 7.4 
containing 0.1% sodium deoxycholate 
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(Calbiochem), 1% NP-40 (Sigma-Aldrich), 1.5 
mM sodium orthovanadate and 1 mM PMSF. 
Samples were incubated for 1 h with Protein A/G-
Sepharose (Amersham Biosc.). After a 5 min 
centrifugation at 200xg, the supernatants were 
incubated with either 3F4 or SP α-PrP antibodies 
at 4 oC and the resulting immunocomplexes were 
captured with Protein A/G-Sepharose and released 
using Laemmli buffer. Proteins (~50 µg per lane) 
were separated by electrophoresis on 13 % SDS-
polyacrylamide gels and blotted onto PVDF 
membranes (150 V, 1 h). The membrane-bound 
proteins were probed with the primary antibody 
followed by mouse True-blot HRP conjugated α-
mouse IgG (1:1000, eBiosciences), goat α-mouse 
HRP-conjugated IgG (1:3000, Sigma) or goat α-
rabbit HRP-conjugated IgG (1:8000, Chemicon), 
and then developed with chemiluminescent 
Chemicon reagents. Data acquisition and analysis 
were carried out using the Bio-Rad ChemiDoc 
equipment. The following primary antibodies and 
dilutions were used: αPrP 3F4 (1:5000, Signet 
Lab), αPrP α-SP (1:1000, provided by D. Harris 
and raised against PrP N-terminal signal peptide), 
α-YFP (1:3000, α-GFP Abcam), α-PDI (1:1000, 
Abcam), α-βCOP (1:1000, Abcam), α-Histone 
H3 (1:2000, Abcam); α-ubiquitin P4D1 (1:200, 
Santa Cruz Biotech), α-SUMO-1 D-11 (1:200, 
Santa Cruz Biotech), and β-actin (1:5000, Sigma-
Aldrich).  
 
Confocal fluorescence microscopy. Cells were 
plated onto glass coverslips, allowed to attach for 
24 h and then transfected for 48 h. Cells were 
fixed with 4% paraformaldehyde in PBS 
containing 5% sucrose for 10 min at room 
temperature and washed three times with PBS. 
Cells were permeabilized and blocked in PBS 
containing 0.5% saponin, 0.1% Triton and 2% 
bovine serum albumin for 10 min at room 
temperature. Cells were incubated with αPrP 3F4 
(1:600) and with α-PDI (1:600) for 1 h at room 
temperature. After three washes with blocking 
buffer, samples were incubated with Alexa-647-
conjugated goat α-mouse IgG (1:800), Alexa-488-
conjugated α-rabbit IgG (1:800), and Hoechst 
33342 (10 µg/ml) in blocking solution for 30 min 
at room temperature. After washing, the 
coverslips were mounted on glass slides with 
ProLong Gold antifade reagent (Molecular 
Probes). Images were captured with a confocal 
microscope (Leica TCS-SP-AOBS-UV) using the 
UV and Ar lasers at 20 mW for excitations at 364 
nm (Hoescht) and 488 nm (Alexa-488), 
respectively, and  the 633 nm line of the He-Ne 
laser at 10 mW for excitation at 647 nm. Image 
analysis was performed using Leica confocal 
software.  
 
Cell proliferation assays and cell cycle analysis. 
For cell growth analysis, cells were co-transfected 
with pEYFP (Clontech) and the plasmid coding 
wild type HaPrP or its mutants. After 48 h of 
transfection, cells were synchronized in G0/G1 by 
serum deprivation for 18 hours and then released 
by serum supplementation for 6 h. Cell 
proliferation was analyzed in 96-well format 
using the BrdU cell proliferation kit (Calbiochem) 
and a MR500 microplate reader (Dynatech). BrdU 
labeling was performed for 6h during the 10% 
FBS stimulation period. Cell cycle profiles were 
determined by flow cytometry using the standard 
measurement of DNA content with propidium 
iodide (PI) in a BD FACS-Calibur cytometer (BD 
Biosciences). In this case, YFP-positive cells were 
selected by cell sorting before PI labelling. Data 
were compared by one- or two-way ANOVA with 
Bonferroni´s post-test analysis using GraphPad 
Prism v 4.0. 
 
RESULTS 
 
N-terminal signal peptides of PrP contain a 
dual methionine motif. N-terminal signal 
peptides display a tripartite organization into n-, 
h- and c-regions, with the hydrophobic central 
region (h-region) essential for co-translation 
membrane integration and translocation process. 
The signal sequences of PrP from different 
species can be classified into three groups on the 
basis of the number of M residues and their 
position with respect to regional boundaries 
(Figure 1). Group I, represented by the rodent 
sequences, contains two M residues at positions 1 
and 15; the second position is in the N-terminal 
side of the c-region. In Group II, represented by 
the human sequence, the two M residues are at 
positions 1 and 8. In this case the second M 
constitutes the N-terminus of the h-region. On the 
contrary, Group III, which is represented by the 
mink sequence, lacks of the second M residue. 
When converted into their cognate mRNA 
sequences, the M residues of the signal sequences 
become AUG codons that could behave as 
translation initiation sites. We also identified two 
in-frame triplets (CUG and GUG coding HaPrP 
L9 and V13) that could sustain translation 
initiation by means of a single base difference. 
These non-AUG codons are conserved in all 
species.  If used, any of these codons could yield 
nascent chains with different cellular fates. 
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The MM motif allows a dual translation start 
and the existence of PrP isoforms. To test 
whether the downstream AUG codons found in 
the signal sequence regions of PrP mRNA in 
group I and group II could sustain translation 
initiation, we generated a series of point mutations 
in both the HaPrP and HuPrP ORFs [Figure 1, 2 
and Table 1]. These mutations consisted of the 
insertion of a C or a G at various positions 
causing a +1 shift in the reading frame (11C12, 
13G14, 16C17), as well as an M-to-S substitution 
(ATG-to-TTC). The reading frame shift mutations 
allow the study of both non-AUG and AUG start 
sites, whereas the M-to-S substitutions permit the 
evaluation of the role of a specific M residue. It 
should be noted that frame shift mutations allow 
translation initiation at either start sites but only 
the product produced from the start site 
downstream from the insertion will proceed to the 
wild type (wt) stop codon and will produce chains 
retaining the 3F4 PrP epitope.  
The results of the translation of the mRNAs 
coding for wt and mutant HaPrP and HuPrP using 
reticulocyte lysates followed by 
immunoprecipitation with 3F4 are shown in 
Figure 2A. In agreement with previous reports, 
wild type HaPrP mRNA was translated into a 
major polypeptide chain of about 26 kDa. Under 
the same conditions, translation of the mRNA 
coding HaPrP(M1S), in which the canonical AUG 
is functionally impaired, and for the reading frame 
shift mutants HaPrP(11C12) and HaPrP(13G14) 
led to the production of a single product of similar 
mass (26 kDa), but with reduced intensity (about 
10-15% of that of the wt). On the contrary, 
translation of the mRNAs coding HaPrP(16C17) 
and HaPrP(M1S,M15S) resulted in the absence of 
any detectable signal. These results support the 
idea that HaPrP mRNA contains a minor 
translation initiation site and that this site is 
located at codon 15, the AUG triplet coding for 
M15. It should be noted that the chains translated 
from M1 and M15 could not be easily 
differentiated by electrophoresis probably as a 
result of the balance between the differences in 
size and hydrophobicity of the chains [25]. 
The translation of wt HuPrP mRNA 
yielded a band corresponding to a polypeptide 
chain of about 27 kDa [Figure 2A]. This band was 
detected using the mRNAs of the HuPrP(M1S) 
and HuPrP(5T6) mutants, but with less intensity. 
On the contrary, this band was not observed using 
the mRNAs of the HuPrP(11T12), HuPrP(13T14), 
HuPrP(16T17) and HuPrP(M1S,M8S) mutants. 
These results show that HuPrP mRNA, as model 
for group II, also contains a minor translation start 
site and that this site is located at codon 8, the 
AUG triplet coding for M8. 
Since the alternative translation start site of 
PrP signal sequences in groups I and II is due to 
the dual methionine motif, it follows that the 
sequences of Group III either lack this capacity or 
utilize a different process.  
 
HaPrP(M15) and HuPrP(M8) isoforms 
account for de novo synthesized CytPrP. To 
unambiguously establish the relationship between 
HaPrP(M15) and HuPrP(M8) and de novo 
synthesized CytPrP, we studied their behavior in 
cell-free biosynthesis assays [Figure 2B, 2C]. 
Figure 2B shows that in contrast to the wt 
mRNAs, the products of mRNAs coding 
HaPrP(M1S) and HuPrP(M1S) mutants and 
translated in the presence of microsomal 
membranes consisted of a single band of ~26 kDa 
that remained unchanged after PNGase F 
digestion. Comparison of the bands after 
deglycosilation, in particular of HuPrP chains, 
suggests that HuPrP(M1S) migrates similarly to 
an unprocessed full length chain (see below) [26]. 
The unglycosylated pattern agrees with a 
cytosolic location for the HaPrP(M15) and 
HuPrP(M8) C-terminal domains. Furthermore, 
external addition of proteinase K to both the total 
reaction mixture and its sealed microsome 
fraction (no signal was detected in this fraction 
even using at a 10x overload compared to the wt) 
resulted in complete degradation of the ~26 kDa 
chains translated from the HaPrP(M15) and 
HuPrP(M8) mRNAs [Figure 2C]. In contrast the 
product translated from wt mRNAs under similar 
conditions showed protected fragments 
corresponding to translocated and integrated PrP 
chains [3]. Taken together, these results suggest 
that HaPrP(M15) and HuPrP(M8) chains 
segregate outside the secretory route under a 
proteinase K-sensitive conformation as described 
for CytPrP. 
To determine whether the synthesis of 
these isoforms takes place in cellular contexts, we 
proceeded with transient transfection experiments 
using CHO and COS-7 cells, which have 
undetectable levels of endogenous PrP expression. 
In this case, the study was restricted to the HaPrP 
sequences for biosafety reasons and was 
performed as co-transfection with pEYFP in order 
to use YFP expression as an internal control. 
Plasmids encoding HaPrP wt and 
HaPrP(M1SM15S) were used as positive and 
negative controls for PrPC expression, 
respectively, whereas those encoding 
HaPrP(11C12) and HaPrP(M1S) were employed 
to assess the functionality of M15 as start site. 
Figure 3A shows that HaPrP(M15) was indeed 
synthesized by cells based on the presence of a 26 
kDa band recognized by αPrP 3F4 in the lysates 
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of HaPrP(11C12) and HaPrP(M1S) transfectants. 
Importantly, the 26 kDa band was also recognized 
by α-SP, an antibody raised against the C-
terminal region of the signal sequence [11]. In cell 
lysates HaPrP(M15) retained the C-terminal 
hydrophobic segment according to electrophoretic 
mobility determinations using a panel of 
recombinant PrP chains consisting in the full 
unprocessed chain (1-254 sequence), fully 
processed chain (23-231 sequence) and N-
terminally shortened chains either containing (15-
254) or lacking (15-231) the C-terminal 
hydrophobic segment [Figure 3B].  
To corroborate that the HaPrP(M15) 
synthesized in cells behaves as CytPrP, we studied 
its glycosylation state as well as its capacity to 
form insoluble aggregates upon proteasome 
impairment [13, 15-17]. Figure 3C shows that in 
contrast to wt HaPrP, 26 kDa HaPrP(M1S) 
remained unchanged upon PNGase F digestion as 
expected for CytPrP. Moreover, both transient and 
irreversible inhibition of the proteasome with 5 
µM MG132 promoted the formation in the cytosol 
of insoluble HaPrP(M1S) aggregates [Figure 3D]. 
Both the absence of glycosylation and the 
capacity to form cytosolic insoluble aggregates 
confirms that HaPrP(M15) behaves as CytPrP in a 
cellular context. 
 
HaPrP(M15) and HuPrP(M8) are found in 
nuclei isolated from cells and normal brain 
homogenates, and are sumoylated. To elucidate 
the properties of these isoforms, we first studied 
their subcellular location using confocal 
microscopy. Unless stated, HaPrP(M15) was 
expressed from the HaPrP(∆14) construct for 
easier detection. Indirect immunofluorescence 
stainings showed that at 48 h after transfection, 
HaPrP(M15) was localized largely to the nuclei of 
cells [Figure 4A]. The distribution pattern agreed 
with the diffuse nucleoplasmic location observed 
for several studied CytPrP models [19, 27], and 
differed from the intranuclear granules observed 
in neuronal cells expressing BoPrPC [28]. The 
nuclear localization was then confirmed by 
subcellular fractionation of cell homogenates. 
Figure 4B shows that about 70% of the expressed 
HaPrP(∆14) was localized to the nuclear fraction, 
mainly as a 26 kDa chain but also as higher 
molecular weight species. Similar results were 
obtained using CHO and COS-7 cells. 
To generalize the nuclear localization of 
HaPrP(M15), as well as to determine the origin of 
the high molecular weight bands, we purified the 
nuclei from normal hamster brain and human 
cortex homogenates and characterized the PrP 
contained therein. Before the analysis the purified 
nuclei were dispersed in EZ-lysis buffer, digested 
with PIPLC and then centrifuged at low speed.  
This process allows the release of the contaminant 
membrane-anchored forms [29], Figure 5A shows 
that after removing raft-resident PrPC, PrP was 
detected in the nuclei purified from hamster brain 
homogenates as two bands of 26 and 35 kDa that 
remained unchanged after enzymatic 
deglycosylation. Nuclear PrP in human cortex was 
also comprised of two major PNGaseF-resistant 
bands of about 26 and 35 kDa. These bands were 
recognized by both 3F4 and α-SP, as expected 
from PrP chains bearing N-terminal shortened 
signal peptides [Figure 5B]. These data confirm 
the existence and nuclear distribution of isoforms 
produced by alternative translation in normal 
tissues. 
The complexity of the bands suggests the 
occurrence of covalent modifications. Of the 
modifications that can occur in nuclear proteins 
and cause increases in size, activity-modifying 
sumoylation and degradation-targeting 
ubiquitinylation were studied. Figure 5C shows 
that high molecular weight bands of PrP 
immunoprecipitated with 3F4 from denatured 
nuclei extracts of hamster brain homogenates 
were recognized by an anti-SUMO-1 antibody but 
not by anti-ubiquitin or anti-SUMO 2/3 
antibodies. Inverse pull-down experiments with 
α-SUMO-I confirmed 3F4 immunorreactivity. 
Since SUMO-1 conjugation involves the covalent 
attachment of a single 9.5 kDa chain, the observed 
band pattern can be explained to large extent by 
considering the composition of a non-sumoylated 
chain (26 kDa) and a SUMO-I conjugated form 
(35 kDa).  
In summary, PrP(M8/M15) appear to be a 
nuclear isoform that acts as substrate for SUMO-1 
conjugation. 
 
HaPrP(M15) expression abrogates cell 
proliferation. Trials to establish cell lines 
expressing HaPrP(M15) were unsuccessful  
despite the absence of a conclusive and 
reproducible cell death event. Stably transfected 
clones were selected, but they failed to grow. 
These growth alterations together with the nuclear 
distribution and involvement of reversible 
sumoylation prompted us to consider a possible 
anti-proliferative activity.  
Analysis of BrdU incorporation showed 
that HaPrP(M15) did indeed decrease cell growth 
as compared to HaPrP wt and the negative control 
HaPrP(M1SM15S)  in both COS-7 and CHO cells 
[Figure 6A]. This effect was more pronounced 
and statistically significantly higher (p<0.001) for 
the HaPrP(∆14) mutant, which overexpresses the 
PrP isoform [Figure 3A], than the HaPrP(M1S) 
and HaPrP(11C12) mutants.  
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The cell cycle was then analyzed using a 
co-transfection approach. In this case cells were 
co-transfected with pEYFP for separation of the 
positive transfectants by cell sorting before PI 
labeling. Figure 6 [panels B and C] shows that 
cells expressing HaPrP(M15) from both 
HaPrP(∆14) and HaPrP(11C12) constructs 
exhibited a higher proportion of cells in the G0/G1 
phase as compared to the mock control 
[transfection with HaPrP(M1SM15S)]. These 
results indicate that HaPrP(M15) functions as a 
growth suppressor that delays the exit from G1 
phase.  
 
 
DISCUSSION 
 
In this study we have shown that the minor 
member of the PrPC family segregating outside 
the secretory route is generated by alternative 
initiation of translation. The presence of a second 
M residue at the h-region boundary of the signal 
sequence determines the alternative translation 
initiation event. This process permits the synthesis 
of an isoform translated from either M15 in 
HaPrP or from M8 in HuPrP. This isoform 
represents a novel chain differing from the 
conventional mature form in the retention of the 
c-region of the N-terminal signal sequence and the 
full C-terminal hydrophobic region. These two 
segments could provide new functions as stability 
regulators or as sites of interaction for distinct 
ligands, among others. 
The use of in-frame alternative translation 
start sites is a relatively common process by 
which proteins encoded by a single mRNA can 
acquire multiplicity of sorting and function under 
environmental regulation [30-34]. Although the 
relative proportion of PrP(M15) synthesis was 
about 12% both in the in vitro studies and cell 
systems used for transfection, it might be 
susceptible to such modulation. This is supported 
by the cell- and regional dependency of CytPrP in 
normal rodent brains as well as its increased 
levels under ER stress [23,35]. As noted the dual 
start site motif is missing in a group of highly 
conserved PrP sequences. In these sequences the 
AUG triplet coding for M15 is found as either 
ACG or ACA, which code for T. Of these two 
codons, ACG can function as a non-AUG start 
site [36,37]. However, the function of the ACA 
triplet as a start is unclear, thus whether ACA-
bearing species use the alternative translation 
mechanism remains to be established.  
Isolating the synthesis of HaPrP(M15) 
from that of the major membrane-bound PrP 
forms allowed three major findings: nuclear 
localization, variable SUMO-1 conjugation, and 
anti-proliferative activity. The nuclear localization 
of this isoform might explain results of previous 
PrP studies describing rare nuclear localization, 
the presence of NLS, and the capacity of the chain 
to interact with nucleic acids and with chromatin 
[19, 28, 38].  
SUMO-1 conjugation of the nuclear 
population of PrP suggests stringent regulation of 
activity and physiological relevance for this 
isoform. In general, sumoylation provides an 
on/off functional switch for protein interactions 
involved in processes such as transport, 
transcriptional silencing, genomic stabilization 
and stress responses [39]. SUMO-1 conjugated 
and free HaPrP(M15) chains might thus represent 
alternative functional states of the molecule. It is 
thus interesting to note that the degree of 
sumoylation in nuclei from brains was higher than 
that in cells. With the limitations imposed by the 
lack of sumoylation control, HaPrP(M15) 
expression might be involved in dysregulation of 
cellular growth resulting in G0/G1 phase arrest.  
The anti-proliferative function of 
HaPrP(M15) expands the physiological role of 
PrPC. Since most cells withdraw from the cell 
cycle in order to differentiate during the G1 phase, 
it is tempting to consider HaPrP(M15) as 
candidate for promotion of G1-phase arrest 
required for cell differentiation in some 
developing tissues [7]. On the other hand, the loss 
of HaPrP(M15) nuclear functionality might favor 
either cell transformation on depletion [8] or cell 
death on cytosolic accumulation [15]. 
HaPrP(M15) can regulate the efficiency of prion 
accumulation, which decreases with cell division 
[40].  
The isolation of the synthesis of this 
isoform from that of other members of the PrPC 
family suggests that each member of this family 
might have different physiological roles and that 
their aberrant cross-talk could also constitute a 
pathogenic mechanism. 
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FIGURE LEGENDS 
 
Figure 1. Alternative translation start sites in the PrP mRNA signal sequence coding 
region. (A) Classification of PrP signal sequence based on the presence of Met residues at the 
h-region boundaries. (B) Potential translation start sites in the HaPrP signal sequence mRNA 
coding region. AUG (thick) and non-AUG (thin) triplets are underlined. Arrows indicate the 
positions of insertions used for reading frame shifts in the generation of the 11C12, 13G14 and 
16C17 mutants.   
 
Figure 2. Translated forms from PrP mRNA. (A) In vitro translation of the mRNA of HaPrP 
wt and HuPrP wt and of their signal sequence mutants. (B) Cell-free synthesis of HaPrP wt, 
HaPrP(M1S), HaPrP(M1SM15S), HuPrP wt and HuPrP(M1S). The HuPrP(M1SM8S) and 
HaPrP(M1SM15S) mutants behaved similarly. Each of the mRNAs was translated in the rabbit 
reticulocyte lysate translation system in the presence of pancreatic microsomes and then 
immunoprecipitated with 3F4 mAb. The immunoprecipitated products were divided into two 
aliquots, one of which was digested with PNGase F as indicated. Relative sample loads are 
indicated at the bottom of the lanes. (C) Accessibility of the translation-translocation products 
of HaPrP wt, HuPrP wt and of their M1S mutants to externally added proteases in the total 
reaction mixtures (left) and in their sealed membrane fractions (SM, right). Each of the mRNAs 
was translated in the rabbit reticulocyte lysate translation system in the presence of pancreatic 
microsomes and then divided in three aliquots: i) untreated, ii) digested with proteinase K, and 
iii) digested with proteinase K in the presence of 0.5% Triton X-100 as a control for full 
accessibility. For SM analysis, HaPrP(M1S) was loaded in a 10x excess compared to HaPrP wt. 
 
Figure 3.  Expression of HaPrP(M15) in CHO cells. (A) Transient expression of HaPrP wt 
and of its mutants in CHO cells. After 48 h of co-transfection with pEYFP, cells were harvested, 
lysed and immunoblotted with antibodies against PrP (3F4), YFP and β-actin, respectively. 
Similar results were obtained using COS-7 cells. (B) Comparison of HaPrP(M1S) with 1-254, 
15-254, 15-231 and 23-231 PrP chains produced in E.coli inclusion bodies by western blot. The 
Tris-Tricine SDS-PAGE was performed using 16.5% gels and the blot was probed with 3F4. 
 -9-
The migration of the recombinant PrP(15-254) chain is depicted with a straight line (C) 
Enzymatic deglycosylation with PNGase F of HaPrP wt and of its M1S mutant. (D) 
Incorporation of HaPrP wt and of its M1S and ∆14 mutants into cytosolic insoluble aggregates 
upon proteasome inhibition. After transfection (30 h), cells were treated in the absence of 
presence of 5µM MG132. Incubation with MG132 was either allowed to proceed for (+24) 24 h 
(irreversible inhibition) or (+4) after 4 h the media was replaced with MG132-free media and 
the incubation was continued for other 16 h (transient inhibition). Insoluble cytosolic aggregates 
were isolated as described in the method section. 
 
Figure 4. Subcellular location of HaPrP(M15) in CHO cells. (A) Indirect 
immunofluorescence of CHO cells transiently transfected with HaPrP(∆14). Fixed and 
permeabilized cells were stained with antibodies against PrP (3F4, red) and PDI (ER marker, 
green), and with the nuclear dye Hoescht (blue). The white bar represents 40 µm. (B) 
Partitioning of PrP between the nuclear (N) and the post-nuclear (PNS) fractions of transiently 
transfected CHO cells with HaPrP wt and its mutants. The displayed immunoblots were probed 
with α−PrP (3F4 and α-SP), α-Histone H3 (nuclear marker, around 17 kDa), and α-PDI (ER 
marker, around 60 kDa) antibodies.  
 
Figure 5. Analysis of the nuclear PrP isoform in normal brain homogenates. (A) Removal 
of raft-bound PrP species from purified nuclei. Nuclei purified from hamster brain homogenates 
were digested with PIPLC and then centrifuged to remove GPI-bound co-purifying proteins. 
PIPLC-treated nuclei were then digested in the absence and presence of PNGase F. The blot was 
probed with 3F4. (B) PrP forms in PIPLC-treated nuclei from human cortex as detected by 3F4 
and SP immunoreactivity. Samples a, b and c correspond to PIPLC-treated nuclear fractions 
purified from control human cortex homogenates. (C) Analysis of the covalent modifications of 
the nuclear PrP isoform. Denatured extracts of nuclei prepared from hamster brain were 
immunoprecipitated with 3F4 α-PrP. Lanes containing similar loads were probed with the 
following antibodies: mouse Trueblot (α-Mo), 3F4 α-PrP, α-SUMO1, α-ubiquitin (α-UB). 
 
Figure 6. HaPrP(M15) expression interferes with cell growth. (A) Effect of the expression of 
HaPrP wt and its mutants on CHO and COS7 cell proliferation measured by BrdU 
incorporation. Data are shown as the mean ± s.d of three independent experiments, each 
performed in triplicate. Data were compared by one-way ANOVA with Bonferroni´s post-test 
analysis using GraphPad Prism v 4.0. Statistically significant differences between groups are 
indicated (* p < 0.05, ** p < 0.01, *** p < 0.001).  (B) Typical cell cycle profile of YFP-
selected CHO cells co-transfected with HaPrP wt and its mutants. YFP-expressing cells, 
separated by cell sorting, were stained with propidium iodide and analyzed by flow cytometry. 
(C) Cell cycle phase distribution of YFP-selected CHO cells expressing HaPrP wt and its 
mutants. Data are shown as the mean ± s.d of two independent experiments performed in 
duplicate. Data were compared by two-way ANOVA with Bonferroni´s post-test analysis using 
GraphPad Prism v 4.0. Statistically significant differences between groups are indicated (*** p 
< 0.001). For both panels, A and B, the relative expression level of the different construct was 
similar to that displayed in Figure 3A. 
Table 1. HaPrP and HuPrP constructs 
The HaPrP ORF, cloned into pcDNA4.1 under BglII/EcoRI targets, and the HuPrP ORF, cloned into 
pcDNA3.1 under BamHI/EcoRI targets, were used as templates for the generation of point, reading shift and 
deletion mutants using standard molecular biology protocols. 
 
 
Name 
 
 
Mutation 
 
Forward oligo 
 
HaPrPwt 
  
HaPrP(M1S) ATG-1-TTC 5´ -GATCTACCTTCGCGAACCTTAGC 
HaPrP(M15S) ATG-15-TTC 5´-CTCTTTGTGGCTTTCTGGACTGATGTTGG 
HaPrP(M1S,M15S) ATG-1-TTC 
ATG-15-TTC 
5´ -CTCTTTGTGGCTTTCTGGACTGATGTTGG 
5´ -CTCTTTGTGGCTTTCTGGACTGATGTTGG 
HaPrP(11C12) +1 shift downstream codon 11 5´-CTGCTGGCACTCCTTTGTGGCTATGTG 
HaPrP(13G14) +1 shift downtream condon 13 5´-GGCACTCTTTGTGGGCTATGTGGACTGATG 
HaPrP(16C17) +1 shift downtream codon 16 5´-GTGGCTATGTGGCACTGATGTTGGC 
HaPrP(∆14) Deletion of the 1-14 region 5´-CTGCTGGCACTCAGATCTATGTGGACTGAT 
 
HuPrP wt 
  
HuPrP(M1S) ATG-1-TTC 5´-GGTACCGAGTTCGGATCCGTCATTTTG 
HuPrP(M8S) ATG-8-TTC 5´-CTTGGCTGCTGGTTCCTGGTTCTCTTTG 
HuPrP(M1S,M8S) ATG-1-TTC 
ATG-8-TTC 
5´-GGTACCGAGTTCGGATCCGTCATTTTG 
5´-CTTGGCTGCTGGTTCCTGGTTCTCTTTG 
HuPrP(5C6)  +1 shift downstream codon 5 5´-GCGAACCTTGGCCTGCTGGATGCTGG 
HuPrP(11C12) +1 shift downstream codon 11 5´-GCTGGATGCTGGTTCTCCTTTGTGGCCACATGG 
HuPrP(13C14) +1 shift downstream codon 13 5´-CTGGTTCTCTTTGTGCGCCACATG 
HuPrP(16C17) +1 shift downstream codon 16 5´-GTGGCCACATGGCAGTGACCTGGGC 
 
 
 
 
Figure 1; Juanes et al. 
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Figure 2; Juanes et al. 
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Figure 4; Juanes et al. 
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